Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 13, 2017 (Event Date); January 19, 2017 (Filing Date)
Subject: Completion of an "Offer to Amend and Exercise" regarding outstanding warrants.
Key Financial Metrics
This filing reports on a capital raise event rather than standard operating performance. Key figures include:
- Total Warrants Tendered: 30,966,350 Original Warrants.
- Total Exercise Price Paid: Approximately $15.5 million.
- Gross Cash Proceeds: Approximately $13.5 million.
- Net Cash Proceeds: Approximately $12.7 million (after deducting agent fees and expenses).
- Warrant Agent Fee: 5% of cash exercise prices paid by participating holders (excluding placement agent warrants).
Material Changes Versus Prior Period
The transaction resulted in significant changes to the company's capital structure:
- Common Stock Outstanding: Increased from 58,159,495 shares to 87,310,154 shares.
- Outstanding Warrants: Decreased from 40,255,234 shares to 9,288,884 shares.
- Warrant Exercise Price: Reduced to $0.50 per share for participating warrants.
- Lock-Up Period: Shares issued upon exercise are subject to a six-month lock-up period preventing sale or short selling without company consent.
Guidance, Outlook, and Risks
Management Commentary: The company successfully concluded the offer to amend and exercise warrants, securing liquidity through the exercise of approximately 31 million warrants. A press release detailing the results was issued on January 19, 2017.
Risks and Contingencies:
- Lock-Up Restrictions: New shareholders face a six-month restriction on selling or shorting the stock.
- Short Sale Restrictions: Participants agreed to refrain from short sales or similar arrangements during the lock-up period.
- Regulatory Status: The issuance of shares was exempt from registration under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D.
Unusual Items: A significant portion of the warrants were exercised on a cashless basis (e.g., 721,987 of $2.00 PA Warrants, 1,424,812 of $1.00 PA Warrants, and 1,774,017 of $0.75 PA Warrants).
Investor Verification Checklist
- Verify the exact number of shares issued versus the number of warrants exercised on a cashless basis to understand the dilution impact.
- Confirm the specific terms of the six-month lock-up agreement and any potential waivers.
- Review the attached Press Release (Exhibit 99.1) for any additional commentary on the use of the $12.7 million in net proceeds.
- Check subsequent filings for the impact of the increased share count on per-share metrics in future earnings reports.